ERYTHROMYCIN STINOPRATE

First approved in 1952

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C40H71NO14.C5H9NO3S
Molecular Weight	953.185
Optical Activity	UNSPECIFIED
Defined Stereocenters	19 / 19
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)N[C@@H](CS)C(O)=O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

InChI

InChIKey=HXKNXCFNAJGZCM-PWOIWMLJSA-N

InChI=1S/C40H71NO14.C5H9NO3S/c1-15-27-40(11,48)33(44)22(5)30(43)20(3)18-38(9,47)35(55-37-32(53-28(42)16-2)26(41(12)13)17-21(4)50-37)23(6)31(24(7)36(46)52-27)54-29-19-39(10,49-14)34(45)25(8)51-29;1-3(7)6-4(2-10)5(8)9/h20-27,29,31-35,37,44-45,47-48H,15-19H2,1-14H3;4,10H,2H2,1H3,(H,6,7)(H,8,9)/t20-,21-,22+,23+,24-,25+,26+,27-,29+,31+,32-,33-,34+,35-,37+,38-,39-,40-;4-/m10/s1

HIDE SMILES / InChI

Molecular Formula	C40H71NO14
Molecular Weight	789.99
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	18 / 18
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C5H9NO3S
Molecular Weight	163.195
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdfhttp://www.przychodnia.pl/el/leki.php3?lek=628
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/7023159 | http://www.polfa-tarchomin.com.pl/wp-content/uploads/2013/07/Ulotka_Davercin-tabletki-powlekane-250mg.pdf | https://www.doz.pl/leki/p2615-Davercin_tabletki

Erythromycin cyclocarbonate (Davercin) is a first generation semi-synthetic erythromycin. It is active against Gram-positive and some Gram-negative microorganisms. Davercin shows comparable or better in vitro potency, low host toxicity and improved pharmacokinetics compared with erythromycin. It is approved for the treatment of acne, atypical pneumonia (caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila), whooping cough (treatment and prevention), urethritis (caused by Ureaplasma urealyticum and Chlamydia trachomatis), gastrointestinal infection caused by Campylobacter spp., short-term infections of the skin and soft tissues (e.g. acne, staphylococcal dermatitis). In streptococcal infections, diphtheria, gonorrhea, early syphilis in patients who are allergic to penicillin, and in the prevention of bacterial endocarditis before the planned dental procedures. Adverse effects are: nausea, vomiting, abdominal pain, diarrhea, skin allergic reactions.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Bacterial 70S ribosome 180 Target ID: CHEMBL2363135 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdf	Binding Agent 1076	14.0 nM [Kd]
Bacterial 70S ribosome 180 Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7023159	Inhibitor 8504
Bacterial 70S ribosome 180 Target ID: CHEMBL2363135 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf	Binding Agent 1076	14.0 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Diphtheria 40 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdf	Curative	Approved 8583	Erythromycin Approved Use Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date 1972
Erythrasma 26 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdf	Curative	Approved 8583	Erythromycin Approved Use Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date 1972
Listeriosis 26 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdf	Curative	Approved 8583	Erythromycin Approved Use Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date 1972
Respiratory tract infections 85 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdf	Curative	Approved 8583	Erythromycin Approved Use Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date 1972
Skin and skin structure infections 81 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdf	Curative	Approved 8583	Erythromycin Approved Use Erythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date 1972
Acne 100 Sources: https://www.doz.pl/leki/p5178-Davercin_zel_plyn	Curative	Approved 8583	Davercin Approved Use For the topical treatment of acne vulgaris
Pneumonia 91 Sources: https://www.doz.pl/leki/p2615-Davercin_tabletki	Curative	Approved 8583	Davercin Approved Use For the topical treatment of pneumonia
Bacterial endocarditis 30 Sources: http://www.przychodnia.pl/el/leki.php3?lek=628	Curative	Approved 8583	Davercin Approved Use Indicated for the treatment of bacterial endocarditis
Staphylococcal dermatitis 26 Sources: https://www.doz.pl/leki/p2615-Davercin_tabletki	Curative	Approved 8583	Davercin Approved Use Unknown
Diphtheria 40 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf	Curative	Approved 8583	E.E.S. Approved Use E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date 1965
Skin and skin structure infections 81 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf	Curative	Approved 8583	E.E.S. Approved Use E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date 1965
Respiratory tract infections 85 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf	Curative	Approved 8583	E.E.S Approved Use E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date 1965
Listeriosis 26 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf	Curative	Approved 8583	E.E.S. Approved Use E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date 1965
Erythrasma 26 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf	Curative	Approved 8583	E.E.S. Approved Use E.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum. Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date 1965

C_max

Value	Dose	Analyte	Population
2.44 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	ERYTHROMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.18 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	ERYTHROMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.99 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/	250 mg 4 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ERYTHROMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.62 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/	250 mg 4 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ERYTHROMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1161.5 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ERYTHROMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1386.1 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ERYTHROMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
6.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	ERYTHROMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	ERYTHROMYCIN serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3544.7 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ERYTHROMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4096.7 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ERYTHROMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.48 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		ERYTHROMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.31 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/062055Orig1s034.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		ERYTHROMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1408521/	healthy, 12 years Health Status: healthy Age Group: 12 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1408521/	Other AEs: Pancreatitis... Other AEs: Pancreatitis Sources: https://pubmed.ncbi.nlm.nih.gov/1408521/
5.3 g 1 times / day single, oral Studied dose Dose: 5.3 g, 1 times / day Route: oral Route: single Dose: 5.3 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16215473/	healthy, 15 years Health Status: healthy Age Group: 15 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/16215473/	Other AEs: Pancreatitis... Other AEs: Pancreatitis Sources: https://pubmed.ncbi.nlm.nih.gov/16215473/
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/241119/	unhealthy, mean age 30 years Health Status: unhealthy Age Group: mean age 30 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/241119/	Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (2.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/241119/
500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/241119/	unhealthy, mean age 30 years Health Status: unhealthy Age Group: mean age 30 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/241119/	Disc. AE: Nausea, Abdominal pain... AEs leading to discontinuation/dose reduction: Nausea (14.6%) Abdominal pain (4.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/241119/
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2140547/	unhealthy, mean age 44 years Health Status: unhealthy Age Group: mean age 44 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2140547/	Disc. AE: Epigastralgia, Nausea... AEs leading to discontinuation/dose reduction: Epigastralgia (grade 2-3, 2.5%) Nausea (grade 3, 3.3%) Vomiting (grade 2, 0.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/2140547/
100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: https://clinicaltrials.gov/ct2/show/NCT02005029	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02005029	Other AEs: Akathisia, Diarrhea... Other AEs: Akathisia (below serious, 1 patient) Diarrhea (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02005029

AEs

AE	Significance	Dose	Population
Pancreatitis		5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1408521/	healthy, 12 years Health Status: healthy Age Group: 12 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/1408521/
Pancreatitis		5.3 g 1 times / day single, oral Studied dose Dose: 5.3 g, 1 times / day Route: oral Route: single Dose: 5.3 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16215473/	healthy, 15 years Health Status: healthy Age Group: 15 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/16215473/
Vomiting	2.8% Disc. AE	500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/241119/	unhealthy, mean age 30 years Health Status: unhealthy Age Group: mean age 30 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/241119/
Nausea	14.6% Disc. AE	500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/241119/	unhealthy, mean age 30 years Health Status: unhealthy Age Group: mean age 30 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/241119/
Abdominal pain	4.9% Disc. AE	500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/241119/	unhealthy, mean age 30 years Health Status: unhealthy Age Group: mean age 30 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/241119/
Vomiting	grade 2, 0.8% Disc. AE	500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2140547/	unhealthy, mean age 44 years Health Status: unhealthy Age Group: mean age 44 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2140547/
Epigastralgia	grade 2-3, 2.5% Disc. AE	500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2140547/	unhealthy, mean age 44 years Health Status: unhealthy Age Group: mean age 44 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2140547/
Nausea	grade 3, 3.3% Disc. AE	500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2140547/	unhealthy, mean age 44 years Health Status: unhealthy Age Group: mean age 44 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2140547/
Akathisia	below serious, 1 patient	100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: https://clinicaltrials.gov/ct2/show/NCT02005029	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02005029
Diarrhea	below serious, 1 patient	100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: https://clinicaltrials.gov/ct2/show/NCT02005029	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02005029

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 P-gp 1741 OATP1B1 1079 OATP1B3 961	CYP3A 220 OAT2 125

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/9231305/	likely
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf#page=10; https://pubmed.ncbi.nlm.nih.gov/10608481/; https://pubmed.ncbi.nlm.nih.gov/9728898/; https://doi.org/10.1016/j.dmpk.2015.05.001 Page: 10.0	moderate [IC50 9.9 uM]	yes (co-administration study) Comment: Erythromycin increased mean Cmax value of simvastatin 3.4 fold and AUC0-24 value 6.2 fold; coadministered erythromycin has been reported to increase AUCs of simvastatin, triazolam, and midazolam 6.2-, 3.6-, and 3.8-fold, respectively; A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf#page=10; https://pubmed.ncbi.nlm.nih.gov/10608481/; https://pubmed.ncbi.nlm.nih.gov/9728898/; https://doi.org/10.1016/j.dmpk.2015.05.001 Page: 10.0
OATP1B1 1095	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17296622/	yes [IC50 217 uM]
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/18027988/	yes [IC50 22.7 uM]
OATP1B3 970	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17296622/	yes [IC50 34 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
OAT2 125	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15708966/	yes
CYP3A 220	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf#page=9 Page: 9.0	yes		likely (co-administration study) Comment: Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf#page=9 Page: 9.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/14674677/

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-0126	http://www.3bsc.com/index/pro_info.php?id=19482
Aaron Chemicals	AR0039Z1	http://www.aaronchem.com/114-07-8
abcr GmbH	AB251852	http://www.abcr.com/shop/en/AB251852
Achemtek	0104-008056	http://www.achemtek.com/114-07-8
Acorn PharmaTech	ACN-048190	http://www.acornpharmatech.com/
Acros Organics	AC227330050	https://www.fishersci.com/shop/products/erythromycin-98-acros-organics/AC227330050
Acros Organics	AC227330250	https://www.fishersci.com/shop/products/erythromycin-98-acros-organics/AC227330250
Acros Organics	AC227331000	https://www.fishersci.com/shop/products/erythromycin-98-acros-organics/AC227331000
Acros Organics	AC343880050	https://www.fishersci.com/shop/products/erythromycin-eur-ph-acros-organics/AC343880050
Acros Organics	AC343880250	https://www.fishersci.com/shop/products/erythromycin-eur-ph-acros-organics-1/AC343880250
AEchem Scientific Corp., USA	AE061269	https://www.aechemsc.com/info_products/AE061269.php
AHH Chemical co.,ltd	API-1112	http://www.ahhchemical.com/product/API-1112.html
Alfa Chemistry	114-07-8	https://www.alfa-chemistry.com/erythromycin-cas-114-07-8-item-289674.htm
Alfa Chemistry	AP114078	https://reagents.alfa-chemistry.com/product/erythromycin-cas-114-07-8-1997.html
Alfa Chemistry	AP114078-A	https://reagents.alfa-chemistry.com/product/erythromycin-standard-solution-cas-114-07-8-1998.html
Alfa Chemistry	AP114078-B	https://reagents.alfa-chemistry.com/product/erythromycin-cas-114-07-8-1999.html
ApexBio Technology	B1939	http://www.apexbt.com/erythromycin.html
Aurora Fine Chemicals LLC	A13.139.732	http://online.aurorafinechemicals.com/info?ID=A13.139.732
Avantor Inc	200006-440	https://us.vwr.com/store/product/18600820/erythromycin
Avantor Inc	97061-220	https://us.vwr.com/store/catalog/product.jsp?catalog_number=97061-220
BioCrick	BCC4778	http://www.biocrick.com/Erythromycin-BCC4778.html
BioSynth	E-3250	https://www.biosynth.com/products/biochemistry/culture-media-additives/products/E-3250.html
BLD Pharm	BD17733	http://www.bldpharm.com/products/114-07-8.html
Boerchem	BC205124	http://www.boerchem.com/?product_34527.html
Chem Scene	CS-2168	http://www.chemscene.com/114-07-8.html
Chemchart	cc-erythromycin	http://chemchart.com/erythromycin-detail.html
ChemMol	30102455	http://www.chemmol.com/chemmol/30102455.html
ChemMol	30102582	http://www.chemmol.com/chemmol/30102582.html
Chemspace	CSSB00000053730	https://chem-space.com/CSSB00000053730
CSNpharm	CSN12503	https://www.csnpharm.com/products/erythromycin.html
DC Chemicals	DC7409	http://www.dcchemicals.com/product_show-E_Mycin.html
eNovation Chemicals	D488558	https://www.enovationchem.com/ProductDetails.asp?ProductID=D488558
eNovation Chemicals	D565961	https://enovationchem.com/ProductDetails.asp?ProductID=D565961
eNovation Chemicals	D916215	https://www.enovationchem.com/ProductDetails.asp?ProductID=D916215
Glentham Life Sciences	GA1145	http://www.glentham.com/products/product/GA1145/
Hairui	HR130758	http://www.hairuichem.com/en/product/114-07-8.html
iChemical	EBD28902	http://www.ichemical.com/products/114-07-8.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN00237041	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00237041
LGC Standards	DRE-A13203490AL-100	https://www.lgcstandards.com/US/en/p/DRE-A13203490AL-100
LGC Standards	DRE-C13203490	https://www.lgcstandards.com/US/en/p/DRE-C13203490
mcule	MCULE-4566208867	https://mcule.com/MCULE-4566208867/
MedChem Express	HY-B0220	https://www.medchemexpress.com/Erythromycin.html
MuseChem	A000680	https://www.musechem.com/product/A000680.html
MuseChem	R007004	https://www.musechem.com/product/R007004.html
Oakwood	94643	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=79817&ExtHyperLink=1
OChem	657	http://www.ocheminc.com/index.php?act=psearch&pid=114E078
Parchem	10930	http://www.parchem.com/chemical-supplier-distributor/Erythromycines-000930.aspx
Parchem	16967	http://www.parchem.com/chemical-supplier-distributor/Erythromycin-006967.aspx
Shanghai Tauto Biotech Co., Ltd	E-0288	http://www.tautobiotech.com/BRM/eProductShow.asp?ArticleID=370
Sigma-Aldrich	1242000_USP	https://www.sigmaaldrich.com/catalog/product/usp/1242000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	45674_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/45674?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	45703_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/45703?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	BP794_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp794?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	E0774_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/e0774?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S527402	http://www.smolecule.com/products/s527402
TCI (Tokyo Chemical Industry)	E0751	http://www.tcichemicals.com/eshop/en/us/commodity/E0751/index.html
THE BioTek	bt-267660	https://www.thebiotek.com/product/inhibitors/bt-267660
VladaChem	VL272699-25G	https://www.vladachem.com/product.php?products=114-07-8
Yuhao Chemical	HL1432	http://www.chemyuhao.com/114-07-8.html

PubMed

Title	Date	PubMed
Drug-induced gallbladder disease. Incidence, aetiology and management.	1992 Jan-Feb	1536697
Hepatotoxicity due to erythromycin ethylsuccinate.	1993 Jan 18	8419773
Receptor for motilin identified in the human gastrointestinal system.	1999 Jun 25	10381885
Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.	2000 Jul	10858333
Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.	2001 Dec	11858397
Bone marrow engraftment: histopathology of hematopoietic reconstitution following allogeneic transplantation in CML patients.	2001 Jan	11193198
Studies on macrolide antibiotics I. Synthesis and antibacterial activity of erythromycin A 9-O-substituted oxime ether derivatives against Mycobacterium avium complex.	2001 Sep	11558597
Dynamics of CD34+ progenitor cells following allogeneic bone marrow transplantation in Ph1+CML--an immunohistochemical study on 113 patients with sequential trephine biopsies.	2002 Jun	12183841
Guaiacylglycerol-7'-O-methyl 8'-vanillic acid ether and related compounds from Boreava orientalis.	2003 Jan-Feb	12597255
A highly chemoselective, diastereoselective, and regioselective epoxidation of chiral allylic alcohols with hydrogen peroxide, catalyzed by sandwich-type polyoxometalates: enhancement of reactivity and control of selectivity by the hydroxy group through metal-alcoholate bonding.	2003 Mar 7	12608784
Ratio of erythro and threo forms of beta-O-4 structures in tension wood lignin.	2003 Nov	14568083
Isolation and antimicrobial susceptibility of Aeromonas salmonicida in rainbow trout (Oncorhynchus mykiss) in turkey hatchery farms.	2003 Sep	14535932
Straightforward synthesis of sphinganines via a serine-derived Weinreb amide.	2004 Apr 30	15104474
Bitterness evaluation of medicines for pediatric use by a taste sensor.	2004 Aug	15304986
Delayed Gastric Emptying in Functional Dyspepsia.	2004 Aug	15238200
[3 + 2] Cycloreversion of bicyclo[m.3.0]alkan-3-on-2-yl-1-oxonium ylides to alkenyloxyketenes. Stereospecific aspect.	2004 Feb 20	14961687
Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids.	2004 Feb 23	15013014
Highly diastereoselective reductive coupling of 2-bromo-2,3,3,3-tetrafluoropropanamide with aldehydes promoted by triphenylphosphine-titanium(IV) isopropoxide. An efficient route to the synthesis of erythro-alpha-fluoro-alpha-(trifluoromethyl)-beta-hydroxy amides.	2004 Jul 23	15255733
Mechanism of beta-silyl diacyl peroxide decomposition: a mild and stereoselective synthesis of beta-silyl esters.	2004 May 28	15152998
Effects of colchicine on the maximum biliary excretion of cholephilic compounds in rats.	2004 Sep	15304119
Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia.	2005	15983426
Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK).	2005 Aug	16041596
On the CH...Cu agostic interaction: chiral copper(II) compounds with ephedrine and pseudoephedrine derivatives.	2005 Aug 14	16041414
On-line identification of sugarcane (Saccharum officinarum L.) methoxyflavones by liquid chromatography-UV detection using post-column derivatization and liquid chromatography-mass spectrometry.	2005 Jul 29	16038194
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Desensitization of the human motilin receptor by motilides.	2005 Jun	15764739
Molecular recognition of sialic acid end groups by phenylboronates.	2005 Jun 20	15838860
[Biological effects of a natural alkyl-diacylglyceride preparation in rats with experimental cardioangiopathy].	2005 Mar-Apr	15934370
Cytotoxicity of neolignans identified in Saururus chinensis towards human cancer cell lines.	2005 May	15931587
Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]).	2005 May	15901346
The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine.	2005 May	15845683

Patents

Sample Use Guides

In Vivo Use Guide

The usual dosage of erythromycin tablets is one 250 mg tablet four times daily in equally spaced doses or one 500 mg tablet every 12 hours. Dosage may be increased up to 4 g per day according to the severity of the infection. However, twice-a-day dosing is not recommended when doses larger than 1 g daily are administered.

Route of Administration: Oral

In Vitro Use Guide

The MIC values for erythromycin were: 0.25-1 ug/ml (Staphylococcus aureus ATCC 29213), 1-4 ug/ml (Enterococcus faecalis ATCC 29212), 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:22:08 GMT 2025` Edited by `admin` on `Mon Mar 31 18:22:08 GMT 2025`
Record UNII	M6S6O570YO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ERYTHROMYCIN STINOPRATE

Official Name

English

ERYSEC

Preferred Name

English

erythromycin stinoprate [INN]

Common Name

English

ERYTHROMYCIN STINOPRATE [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

M6S6O570YO